Fifth Third Bancorp Summit Therapeutics Inc. Transaction History
Fifth Third Bancorp
- $25.9 Billion
- Q1 2025
A detailed history of Fifth Third Bancorp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 3,000 shares of SMMT stock, worth $70,050. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000
Previous 200
1400.0%
Holding current value
$70,050
Previous $3,000
1800.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.2MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$570 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$273 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$184 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$153 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$131 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.7B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...